Clinical Trials

290 enrolled

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

140 enrolled

Multiple Myeloma

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

21 enrolled

Multiple Myeloma

NCT07400744 2026-02-10

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

102 enrolled

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

15 enrolled 15 charts

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

317 enrolled

Multiple Myeloma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

15 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04910568 2025-12-24

CAMMA 1

126 enrolled

Multiple Myeloma

NCT06042725 2025-12-24

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

100 enrolled

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05363111 2025-10-29

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

15 enrolled

Multiple Myeloma

NCT07221032 2025-10-27

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

12 enrolled

Multiple Myeloma

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Multiple Myeloma, Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

BreastDermatologicLymphoid

17 enrolled

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT04892264 2025-05-18

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

5 enrolled

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

240 enrolled 2 FDA

Multiple Myeloma

NCT06622005 2025-04-16

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

15 enrolled

Multiple Myeloma

NCT04972942 2025-03-13

ALLO-T-DART

LymphoidOther hematologic neoplasm

30 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05243342 2025-02-17

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

18 enrolled

Multiple Myeloma

NCT02918331 2025-02-03

A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

7 enrolled

Multiple Myeloma

NCT04667663 2025-01-09

CPD-DARA

16 enrolled

Multiple Myeloma

NCT04714372 2024-10-24

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Other hematologic neoplasm

9 enrolled 16 charts

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT05679258 2024-06-28

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

172 enrolled

Multiple Myeloma

NCT04956302 2024-06-06

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

1 enrolled

Multiple Myeloma

NCT03177460 2024-05-03

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

33 enrolled

Genitourinary

Prostatic Neoplasms

NCT03311828 2024-03-12

Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

12 enrolled

Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT04136756 2023-06-15

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

30 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04045028 2023-04-07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

41 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphoma, B-Cell

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT04280328 2022-03-11

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

7 enrolled

Multiple Myeloma

NCT02431208 2021-04-02

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

85 enrolled

Multiple Myeloma

NCT03068351 2020-02-07

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

24 enrolled

Multiple Myeloma

NCT02497378 2019-03-07

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

8 enrolled

Other hematologic neoplasmPlasma cell

Multiple Myeloma

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Leukemia, Plasma Cell

NCT02955810 2018-03-29

CyBorD-Dara

Phase 1 Unknown

18 enrolled

Multiple Myeloma

NCT02116569 2016-09-26

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

9 enrolled